SCHEMBL2395910

SCHEMBL2395910

Cc1nc(Nc2cnccn2)sc1-c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
PIK3CD O00329 2/20 0.58
PIK3CA P42336 2/20 0.58
PIK3CB P42338 2/20 0.58
PIK3CG P48736 2/20 0.58
CCNT1 O60563 7/20 0.47
CCNA2 P20248 7/20 0.47
CDK2 P24941 7/20 0.47
CDK9 P50750 7/20 0.47
CCNA1 P78396 7/20 0.47
CDK1 P06493 6/20 0.42
CCNB1 P14635 6/20 0.42
CDK7 P50613 6/20 0.42
CCNH P51946 6/20 0.42
CCNB2 O95067 1/20 0.41
CCNE2 O96020 1/20 0.41
CCNE1 P24864 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
PTGS2 P35354 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396335 0.90 PIK3CD (0.57) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2398099 0.88 MEN1 (0.45) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2399934 0.87 MEN1 (0.53) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2395892 0.85 MEN1 (0.67) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2395156 0.83 CDK2 (0.59) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2398117 0.83 PIK3CD (0.50) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2395311 0.83 PIK3C2G (0.42) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2398032 0.83 PIK3CD (0.47) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL1888443 0.83 NPC1 (0.48) MEN1KMT2APIK3CDPIK3CAPIK3CB
SCHEMBL2397871 0.82 MEN1 (0.69) MEN1KMT2APIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 MEN1 1758/4885KMT2A 2160/4885PIK3CD 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.